{"title":"拉米夫定再访:高剂量拉米夫定长期治疗相对低病毒血症乙型肝炎患者","authors":"","doi":"10.33140/mcr.05.11.03","DOIUrl":null,"url":null,"abstract":"Hepatitis B virus (HBV) is a significant global health problem with more than 350 million people chronically infected. Currently it is believed that HBV is responsible for 50% of hepatocellular carcinoma (HCC) worldwide [1-3]. While a cure for HBV is still needed, several oral drugs that suppress viral replication exist. In the United States, six nucleos(t)ide analogues that have been approved at different time periods include lamivudine (1998), adefovir (2002), entecavir (2005), telbivudine (2006), tenofovir disoproxil fumarate (2008) and tenofovir alafenamide (2016).","PeriodicalId":9304,"journal":{"name":"British Medical Journal (Clinical research ed.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Lamivudine Revisited: Long-Term Treatment of Relatively Low-Viremic Hepatitis B Patients on Higher-Dose Lamivudine\",\"authors\":\"\",\"doi\":\"10.33140/mcr.05.11.03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hepatitis B virus (HBV) is a significant global health problem with more than 350 million people chronically infected. Currently it is believed that HBV is responsible for 50% of hepatocellular carcinoma (HCC) worldwide [1-3]. While a cure for HBV is still needed, several oral drugs that suppress viral replication exist. In the United States, six nucleos(t)ide analogues that have been approved at different time periods include lamivudine (1998), adefovir (2002), entecavir (2005), telbivudine (2006), tenofovir disoproxil fumarate (2008) and tenofovir alafenamide (2016).\",\"PeriodicalId\":9304,\"journal\":{\"name\":\"British Medical Journal (Clinical research ed.)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Medical Journal (Clinical research ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/mcr.05.11.03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Medical Journal (Clinical research ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/mcr.05.11.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lamivudine Revisited: Long-Term Treatment of Relatively Low-Viremic Hepatitis B Patients on Higher-Dose Lamivudine
Hepatitis B virus (HBV) is a significant global health problem with more than 350 million people chronically infected. Currently it is believed that HBV is responsible for 50% of hepatocellular carcinoma (HCC) worldwide [1-3]. While a cure for HBV is still needed, several oral drugs that suppress viral replication exist. In the United States, six nucleos(t)ide analogues that have been approved at different time periods include lamivudine (1998), adefovir (2002), entecavir (2005), telbivudine (2006), tenofovir disoproxil fumarate (2008) and tenofovir alafenamide (2016).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
